Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis.
Identifieur interne : 005017 ( PubMed/Checkpoint ); précédent : 005016; suivant : 005018Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis.
Auteurs : A P Limaye [États-Unis] ; E A Ottesen ; V. Kumaraswami ; J S Abrams ; J. Regunathan ; V. Vijayasekaran ; K. Jayaraman ; T B NutmanSource :
- The Journal of infectious diseases [ 0022-1899 ] ; 1993.
Descripteurs français
- KwdFr :
- 12-Myristate-13-acétate de phorbol (pharmacologie), Adolescent, Adulte, Cinétique, Diéthylcarbamazine (usage thérapeutique), Filariose lymphatique (immunologie), Filariose lymphatique (traitement médicamenteux), Granulocytes éosinophiles (métabolisme), Humains, Interleukine-5 (métabolisme), Interleukine-5 (sang), Ionomycine (pharmacologie), Mâle, Éosinophilie (immunologie).
- MESH :
- immunologie : Filariose lymphatique, Éosinophilie.
- métabolisme : Granulocytes éosinophiles, Interleukine-5.
- pharmacologie : 12-Myristate-13-acétate de phorbol, Ionomycine.
- sang : Interleukine-5.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Diéthylcarbamazine.
- Adolescent, Adulte, Cinétique, Humains, Mâle.
English descriptors
- KwdEn :
- Adolescent, Adult, Diethylcarbamazine (therapeutic use), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (immunology), Eosinophilia (immunology), Eosinophils (metabolism), Humans, Interleukin-5 (blood), Interleukin-5 (metabolism), Ionomycin (pharmacology), Kinetics, Male, Tetradecanoylphorbol Acetate (pharmacology).
- MESH :
- chemical , blood : Interleukin-5.
- chemical , metabolism : Interleukin-5.
- chemical , pharmacology : Ionomycin, Tetradecanoylphorbol Acetate.
- chemical , therapeutic use : Diethylcarbamazine.
- drug therapy : Elephantiasis, Filarial.
- immunology : Elephantiasis, Filarial, Eosinophilia.
- metabolism : Eosinophils.
- Adolescent, Adult, Humans, Kinetics, Male.
Abstract
Peripheral blood eosinophil counts and serum levels and in vitro production of eosinophilopoietic cytokines were assessed before and at frequent intervals after diethylcarbamazine treatment of Bancroftian filariasis. Eosinophil counts peaked at day 7 after the start of treatment (359% +/- 118% of pretreatment levels) and declined to pretreatment levels by day 17. Serum interleukin (IL)-5, undetectable in 14 of 15 patients before treatment, rose sharply but transiently, with peak levels (32 +/- 7 pg/mL) 2 days after diethylcarbamazine treatment. Granulocyte-macrophage colony-stimulating factor and IL-3 were not detectable in serum at any time. In vitro mitogen-induced IL-5 levels decreased significantly in 7 of 9 patients 3 days after treatment when serum IL-5 was at near-peak levels. By day 10 IL-5 values increased in 8 of 9 patients compared with treatment values (P < .02). These data define the temporal relation between serum IL-5 levels and the subsequent development of eosinophilia and suggest that lymphocytes are the source of IL-5.
PubMed: 8501330
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:8501330Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis.</title><author><name sortKey="Limaye, A P" sort="Limaye, A P" uniqKey="Limaye A" first="A P" last="Limaye">A P Limaye</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Ottesen, E A" sort="Ottesen, E A" uniqKey="Ottesen E" first="E A" last="Ottesen">E A Ottesen</name></author><author><name sortKey="Kumaraswami, V" sort="Kumaraswami, V" uniqKey="Kumaraswami V" first="V" last="Kumaraswami">V. Kumaraswami</name></author><author><name sortKey="Abrams, J S" sort="Abrams, J S" uniqKey="Abrams J" first="J S" last="Abrams">J S Abrams</name></author><author><name sortKey="Regunathan, J" sort="Regunathan, J" uniqKey="Regunathan J" first="J" last="Regunathan">J. Regunathan</name></author><author><name sortKey="Vijayasekaran, V" sort="Vijayasekaran, V" uniqKey="Vijayasekaran V" first="V" last="Vijayasekaran">V. Vijayasekaran</name></author><author><name sortKey="Jayaraman, K" sort="Jayaraman, K" uniqKey="Jayaraman K" first="K" last="Jayaraman">K. Jayaraman</name></author><author><name sortKey="Nutman, T B" sort="Nutman, T B" uniqKey="Nutman T" first="T B" last="Nutman">T B Nutman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8501330</idno><idno type="pmid">8501330</idno><idno type="wicri:Area/PubMed/Corpus">005717</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005717</idno><idno type="wicri:Area/PubMed/Curation">005717</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005717</idno><idno type="wicri:Area/PubMed/Checkpoint">005717</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005717</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis.</title><author><name sortKey="Limaye, A P" sort="Limaye, A P" uniqKey="Limaye A" first="A P" last="Limaye">A P Limaye</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Ottesen, E A" sort="Ottesen, E A" uniqKey="Ottesen E" first="E A" last="Ottesen">E A Ottesen</name></author><author><name sortKey="Kumaraswami, V" sort="Kumaraswami, V" uniqKey="Kumaraswami V" first="V" last="Kumaraswami">V. Kumaraswami</name></author><author><name sortKey="Abrams, J S" sort="Abrams, J S" uniqKey="Abrams J" first="J S" last="Abrams">J S Abrams</name></author><author><name sortKey="Regunathan, J" sort="Regunathan, J" uniqKey="Regunathan J" first="J" last="Regunathan">J. Regunathan</name></author><author><name sortKey="Vijayasekaran, V" sort="Vijayasekaran, V" uniqKey="Vijayasekaran V" first="V" last="Vijayasekaran">V. Vijayasekaran</name></author><author><name sortKey="Jayaraman, K" sort="Jayaraman, K" uniqKey="Jayaraman K" first="K" last="Jayaraman">K. Jayaraman</name></author><author><name sortKey="Nutman, T B" sort="Nutman, T B" uniqKey="Nutman T" first="T B" last="Nutman">T B Nutman</name></author></analytic><series><title level="j">The Journal of infectious diseases</title><idno type="ISSN">0022-1899</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Diethylcarbamazine (therapeutic use)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (immunology)</term><term>Eosinophilia (immunology)</term><term>Eosinophils (metabolism)</term><term>Humans</term><term>Interleukin-5 (blood)</term><term>Interleukin-5 (metabolism)</term><term>Ionomycin (pharmacology)</term><term>Kinetics</term><term>Male</term><term>Tetradecanoylphorbol Acetate (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>12-Myristate-13-acétate de phorbol (pharmacologie)</term><term>Adolescent</term><term>Adulte</term><term>Cinétique</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Filariose lymphatique (immunologie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Granulocytes éosinophiles (métabolisme)</term><term>Humains</term><term>Interleukine-5 (métabolisme)</term><term>Interleukine-5 (sang)</term><term>Ionomycine (pharmacologie)</term><term>Mâle</term><term>Éosinophilie (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Interleukin-5</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interleukin-5</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Ionomycin</term><term>Tetradecanoylphorbol Acetate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Éosinophilie</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Eosinophilia</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Eosinophils</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Granulocytes éosinophiles</term><term>Interleukine-5</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>12-Myristate-13-acétate de phorbol</term><term>Ionomycine</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Interleukine-5</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diéthylcarbamazine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Humans</term><term>Kinetics</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Cinétique</term><term>Humains</term><term>Mâle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Peripheral blood eosinophil counts and serum levels and in vitro production of eosinophilopoietic cytokines were assessed before and at frequent intervals after diethylcarbamazine treatment of Bancroftian filariasis. Eosinophil counts peaked at day 7 after the start of treatment (359% +/- 118% of pretreatment levels) and declined to pretreatment levels by day 17. Serum interleukin (IL)-5, undetectable in 14 of 15 patients before treatment, rose sharply but transiently, with peak levels (32 +/- 7 pg/mL) 2 days after diethylcarbamazine treatment. Granulocyte-macrophage colony-stimulating factor and IL-3 were not detectable in serum at any time. In vitro mitogen-induced IL-5 levels decreased significantly in 7 of 9 patients 3 days after treatment when serum IL-5 was at near-peak levels. By day 10 IL-5 values increased in 8 of 9 patients compared with treatment values (P < .02). These data define the temporal relation between serum IL-5 levels and the subsequent development of eosinophilia and suggest that lymphocytes are the source of IL-5.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8501330</PMID><DateCreated><Year>1993</Year><Month>06</Month><Day>29</Day></DateCreated><DateCompleted><Year>1993</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1899</ISSN><JournalIssue CitedMedium="Print"><Volume>167</Volume><Issue>6</Issue><PubDate><Year>1993</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis.</ArticleTitle><Pagination><MedlinePgn>1396-400</MedlinePgn></Pagination><Abstract><AbstractText>Peripheral blood eosinophil counts and serum levels and in vitro production of eosinophilopoietic cytokines were assessed before and at frequent intervals after diethylcarbamazine treatment of Bancroftian filariasis. Eosinophil counts peaked at day 7 after the start of treatment (359% +/- 118% of pretreatment levels) and declined to pretreatment levels by day 17. Serum interleukin (IL)-5, undetectable in 14 of 15 patients before treatment, rose sharply but transiently, with peak levels (32 +/- 7 pg/mL) 2 days after diethylcarbamazine treatment. Granulocyte-macrophage colony-stimulating factor and IL-3 were not detectable in serum at any time. In vitro mitogen-induced IL-5 levels decreased significantly in 7 of 9 patients 3 days after treatment when serum IL-5 was at near-peak levels. By day 10 IL-5 values increased in 8 of 9 patients compared with treatment values (P < .02). These data define the temporal relation between serum IL-5 levels and the subsequent development of eosinophilia and suggest that lymphocytes are the source of IL-5.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Limaye</LastName><ForeName>A P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ottesen</LastName><ForeName>E A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Kumaraswami</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Abrams</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Regunathan</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vijayasekaran</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Jayaraman</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nutman</LastName><ForeName>T B</ForeName><Initials>TB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015848">Interleukin-5</NameOfSubstance></Chemical><Chemical><RegistryNumber>56092-81-0</RegistryNumber><NameOfSubstance UI="D015759">Ionomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>NI40JAQ945</RegistryNumber><NameOfSubstance UI="D013755">Tetradecanoylphorbol Acetate</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004802" MajorTopicYN="N">Eosinophilia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004804" MajorTopicYN="N">Eosinophils</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015848" MajorTopicYN="N">Interleukin-5</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015759" MajorTopicYN="N">Ionomycin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013755" MajorTopicYN="N">Tetradecanoylphorbol Acetate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8501330</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><noCountry><name sortKey="Abrams, J S" sort="Abrams, J S" uniqKey="Abrams J" first="J S" last="Abrams">J S Abrams</name><name sortKey="Jayaraman, K" sort="Jayaraman, K" uniqKey="Jayaraman K" first="K" last="Jayaraman">K. Jayaraman</name><name sortKey="Kumaraswami, V" sort="Kumaraswami, V" uniqKey="Kumaraswami V" first="V" last="Kumaraswami">V. Kumaraswami</name><name sortKey="Nutman, T B" sort="Nutman, T B" uniqKey="Nutman T" first="T B" last="Nutman">T B Nutman</name><name sortKey="Ottesen, E A" sort="Ottesen, E A" uniqKey="Ottesen E" first="E A" last="Ottesen">E A Ottesen</name><name sortKey="Regunathan, J" sort="Regunathan, J" uniqKey="Regunathan J" first="J" last="Regunathan">J. Regunathan</name><name sortKey="Vijayasekaran, V" sort="Vijayasekaran, V" uniqKey="Vijayasekaran V" first="V" last="Vijayasekaran">V. Vijayasekaran</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Limaye, A P" sort="Limaye, A P" uniqKey="Limaye A" first="A P" last="Limaye">A P Limaye</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005017 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 005017 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:8501330
|texte= Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:8501330" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |